Sihuan Pharmaceutical Holdings Group (HK:0460) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sihuan Pharmaceutical Holdings Group Ltd. has announced an exclusive licensing deal through its subsidiary, Xuanzhu Biopharm, with Livzon Pharma for the development and commercialization of the innovative drug Fadanafil in Greater China and other non-regulatory markets. Fadanafil, a promising treatment for erectile dysfunction and pulmonary hypertension, is entering Phase I clinical trials and offers a significant improvement over existing medications with fewer side effects. Xuanzhu Biopharm retains rights to Fadanafil in major markets including Europe and the US, and will receive upfront payments as well as milestone and sales-based royalties.
For further insights into HK:0460 stock, check out TipRanks’ Stock Analysis page.